HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Costs Would Snowball With User Fees For Cosmetics Firms – Attorneys

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic manufacturers could be facing a raft of new expenses if user-fee legislation passes, attorneys say. With increased funding, FDA could move the cosmetics industry toward a regulatory framework like the 510(k) premarket notification system in place for medical devices, Arent Fox’s Georgia Ravitz suggests.

You may also be interested in...



Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

Rep. Lance, Council Work To Generate Support For Cosmetics Bill

New Jersey Rep. Leonard Lance will discuss his cosmetics bill, the Cosmetic Safety Amendments Act, with L’Oreal employees at a news conference on May 7. The bill is also backed by the Personal Care Products Council, which is working to gain legislative support from both parties.

Council-Approved Cosmetics Safety Bill Launches

Rep. Leonard Lance, R-N.J., introduces the Cosmetic Safety Amendments Act of 2012, with “the full support” of the Personal Care Products Council. Bill would not require manufacturers to substantiate product safety prior to market or pay user fees, but it does include registration, ingredient disclosure and adverse-event reporting requirements and proposes a significant increase in FDA’s oversight role.

Related Content

UsernamePublicRestriction

Register

RS018059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel